—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Vertex Pharmaceuticals Inc (VRTX) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for VRTX, from the same nightly bakes the boards use. Research diary readings, not advice.

Versus its index HALO Growth 100 — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

HALO Growth 100 · as of 2026-10-06

DayWeekMonth3 months
VRTX−0.2%−4.6%−8.0%+0.8%
Longevity & Healthspan−1.9%−3.5%−4.0%—
HALO Growth 100+0.5%+0.7%−4.9%—

Against the index: 5.3 pts behind on the week, 3.1 pts behind on the month; against its Longevity & Healthspan sleeve 4.0 pts behind on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Mentioned on Closelooknet 1 piece · newest: Midday 10, “A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000” (2026-08-21)

Mentioned on Closelooknet

Where VRTX appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.61 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How VRTX has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.61 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Vertex Pharmaceuticals Inc moved 0.61% on average · correlation 0.20 · higher than 63% of US names
  • Beta, last 3 months 0.63 about the same as over the year
  • On the 10 worst bond days −0.88% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +1.17% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against HALO Growth 100 · Longevity & Healthspan · 8 names with week and year-to-date

Peer group

HALO Growth 100 · Longevity & Healthspan

GLP-1 leaders, gene-editing platforms, diagnostics-at-scale, biopharma compounders. Demographics writes the demand curve.

Compared against VRTX on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Vertex Pharmaceuticals Inc

VRTX in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Vertex Pharmaceuticals is a biotechnology company that sells drugs for cystic fibrosis, a lung and digestive disease caused by a faulty gene, including its main products Trikafta and Kaftrio. It also markets Casgevy, a gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia, and Journavx for acute pain. Its pipeline extends into kidney disease, diabetes and other rare conditions still in clinical trials. It sells through specialty pharmacies, distributors, hospitals and clinics, and is based in Boston.
Where it sits in the stack
Vertex has no seat in Rubin, our AI build-out index; it sits instead in the HALO Growth 100, our growth index outside the megacaps, in the Longevity & Healthspan sleeve, which groups drugmakers and diagnostics firms whose demand follows population ageing rather than the semiconductor cycle.
Who it is priced against
Closelooknet's peer group places it with other biopharma compounders and diagnostics-at-scale names built on demographic demand — Eli Lilly, Regeneron, Zealand Pharma, Illumina, Novo Nordisk, Amgen, Natera and Gerresheimer; the market also names Gilead Sciences as a comparable specialty biotech.
Why Closelooknet tracks it
It holds seats in the HALO Growth 100 and the Nasdaq-100, and carries a Closelooknet score, our multi-module company rating, with quality the strongest module and valuation the weakest. The diary has referenced it once, in a Midday 10 edition noting breadth across health care and biotech names.
What the diary watches
Whether Casgevy and Journavx build volume at the pace the cystic fibrosis franchise once did, since that would change how the diary weighs the growth read against the valuation module.

Vertex Pharmaceuticals Inc (VRTX) trades on US exchanges. Constituent of HALO Growth 100.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: VRTX news on the tape · index compare · sector dispersion · scanner.

The Street on this name 3 analyst actions on the wire · latest: price target by UBS, 2026-09-28

The Street on this name

Analyst actions and the latest print for VRTX from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target UBS — target 615 from 585 Target raised to $615 from $585 (+16.5% to spot) 2026-09-28
  • Price target Jefferies — target 640 Target set to $640 (+24.3% to spot) 2026-09-23
  • Price target Morgan Stanley — target 665 Target set to $665 (+21.4% to spot) 2026-09-01

3 actions on the analyst wire since 2026-08-13: 3 target changes. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Vertex Pharmaceuticals Inc (VRTX)?

Vertex Pharmaceuticals Inc trades as VRTX on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is VRTX in a Closelooknet index?

Yes — Vertex Pharmaceuticals Inc is a constituent of HALO Growth 100, as of 2026-10-07.

Where does VRTX trade against its moving averages?

5-day losing streak: Down 5 sessions running. As of 2026-10-05 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is VRTX doing against its Closelooknet index?

Over the past month Vertex Pharmaceuticals Inc is −8.0% against −4.9% for the HALO Growth 100 — 3.1 points behind its index, as of 2026-10-06. Its Longevity & Healthspan sleeve is −4.0% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

How does Vertex Pharmaceuticals Inc compare with its peers?

Against its peer group (HALO Growth 100 · Longevity & Healthspan), Vertex Pharmaceuticals Inc (VRTX) sits 10.1% below its 52-week high, 2.9% below its 50-day average; Eli Lilly and Company (LLY) is 11.6% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below, Amgen Inc (AMGN) is 9.9% below. Put any of them next to VRTX in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Vertex Pharmaceuticals Inc trade when bond yields rise?

Over the past year Vertex Pharmaceuticals Inc had a beta of 0.61 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 63% of US names. On the 10 sessions in which long bonds fell most it moved −0.88% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Vertex Pharmaceuticals Inc?

Vertex Pharmaceuticals Inc appears in 1 Closelooknet piece, most recently Midday 10: A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000 (2026-08-21). What Closelooknet said most recently: Barchart's large-cap 52-week new-high list, as of 11:59 CDT, carries 31 names and reads like the ex-tech thesis printed as breadth: twelve are health care, biotech or pharma — ARGX, BDX, BIO, CORT, HALO, MRK, REGN, RVTY, THC, TVTX, TXG… (Midday 10, 2026-08-21). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does Vertex Pharmaceuticals Inc do?

Vertex Pharmaceuticals is a biotechnology company that sells drugs for cystic fibrosis, a lung and digestive disease caused by a faulty gene, including its main products Trikafta and Kaftrio. It also markets Casgevy, a gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia, and Journavx for acute pain. Its pipeline extends into kidney disease, diabetes and other rare conditions still in clinical trials. Closelooknet's peer group places it with other biopharma compounders and diagnostics-at-scale names built on demographic demand — Eli Lilly, Regeneron, Zealand Pharma, Illumina, Novo Nordisk, Amgen, Natera and Gerresheimer; the market also names Gilead Sciences as a comparable specialty biotech.

Where does Vertex Pharmaceuticals Inc sit in the AI build-out?

Vertex has no seat in Rubin, our AI build-out index; it sits instead in the HALO Growth 100, our growth index outside the megacaps, in the Longevity & Healthspan sleeve, which groups drugmakers and diagnostics firms whose demand follows population ageing rather than the semiconductor cycle. It holds seats in the HALO Growth 100 and the Nasdaq-100, and carries a Closelooknet score, our multi-module company rating, with quality the strongest module and valuation the weakest. The diary has referenced it once, in a Midday 10 edition noting breadth across health care and biotech names.

What has Wall Street done on Vertex Pharmaceuticals Inc recently?

The most recent analyst action on Vertex Pharmaceuticals Inc on the Closelooknet wire is a price target by UBS on 2026-09-28 (target 615 from 585). 3 actions on the analyst wire since 2026-08-13: 3 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for VRTX, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

same Closelooknet index seat first, then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.